Ablation therapies are widely used in clinical practice for local tumor inactivation, including benign and malignant tumors in various parts of the body, such as lung cancer, liver cancer, kidney cancer and prostate cancer, etc. They are less invasive, have high local efficacy, have fast recovery and can be repeatedly applied, especially for patients who cannot undergo surgery or have multiple lesions. A large number of studies have found that the commonly used cryoablation, radiofrequency ablation, microwave ablation and irreversible electroporation techniques can inactivate tumors in situ while causing changes in systemic immune function and enhancing the body's anti-tumor immune response. This research topic aims to provide a forum for the latest advances in various types of local physical ablation and immune-related research.
The enhanced anti-tumor immune effect after tumor ablation has received more and more attention and confirmation in recent years, especially the synergistic anti-tumor effect played by the combined application of tumor ablation and immunotherapy, which brings new options for tumor treatment. The mechanisms of this synergistic effect are still unclear. In this research topic, we hope to focus on the relationship between tumor ablation and immunity, aiming to bring together researchers in this field to establish a broad and comprehensive landscape of tumor ablation and immunity.
We welcome the submission of Review, Original Research, Perspective, Clinical Trial, and Case Report covering, but not limited to, the following sub-topics:
- Tumor cryoablation combined with immunotherapy for solid tumors
- Immune response to tumor radiofrequency ablation and combined application with immunotherapy
- Immune response caused by tumor microwave ablation
- Irreversible electroporation and tumor immunity
- Laser ablation and tumor immunity
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Ablation therapies are widely used in clinical practice for local tumor inactivation, including benign and malignant tumors in various parts of the body, such as lung cancer, liver cancer, kidney cancer and prostate cancer, etc. They are less invasive, have high local efficacy, have fast recovery and can be repeatedly applied, especially for patients who cannot undergo surgery or have multiple lesions. A large number of studies have found that the commonly used cryoablation, radiofrequency ablation, microwave ablation and irreversible electroporation techniques can inactivate tumors in situ while causing changes in systemic immune function and enhancing the body's anti-tumor immune response. This research topic aims to provide a forum for the latest advances in various types of local physical ablation and immune-related research.
The enhanced anti-tumor immune effect after tumor ablation has received more and more attention and confirmation in recent years, especially the synergistic anti-tumor effect played by the combined application of tumor ablation and immunotherapy, which brings new options for tumor treatment. The mechanisms of this synergistic effect are still unclear. In this research topic, we hope to focus on the relationship between tumor ablation and immunity, aiming to bring together researchers in this field to establish a broad and comprehensive landscape of tumor ablation and immunity.
We welcome the submission of Review, Original Research, Perspective, Clinical Trial, and Case Report covering, but not limited to, the following sub-topics:
- Tumor cryoablation combined with immunotherapy for solid tumors
- Immune response to tumor radiofrequency ablation and combined application with immunotherapy
- Immune response caused by tumor microwave ablation
- Irreversible electroporation and tumor immunity
- Laser ablation and tumor immunity
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.